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Histone acetylation plays an important role in regulating gene transcription and silencing in Plasmodium
falciparum. Histone deacetylase (HDAC) inhibitors, particularly those of the hydroxamate class, have been
shown to have potent in vitro activity against drug-resistant and -sensitive laboratory strains of P. falciparum,
raising their potential as a new class of antimalarial compounds. In the current study, stage-specific ex vivo
susceptibility profiles of representative hydroxamate-based HDAC inhibitors suberoylanilide hydroxamic acid
(SAHA), 2-ASA-9, and 2-ASA-14 (2-ASA-9 and 2-ASA-14 are 2-aminosuberic acid-based HDAC inhibitors)
were assessed in multidrug-resistant clinical isolates of P. falciparum (n  24) and P. vivax (n  25) from
Papua, Indonesia, using a modified schizont maturation assay. Submicromolar concentrations of SAHA,
2-ASA-9, and 2-ASA-14 inhibited the growth of both P. falciparum (median 50% inhibitory concentrations
[IC50s] of 310, 533, and 266 nM) and P. vivax (median IC50s of 170, 503, and 278 nM). Inverse correlation
patterns between HDAC inhibitors and chloroquine for P. falciparum and mefloquine for P. vivax indicate
species-specific susceptibility profiles for HDAC inhibitors. These HDAC inhibitors were also found to be
potent ex vivo against P. vivax schizont maturation, comparable to that in P. falciparum, suggesting that HDAC
inhibitors may be promising candidates for antimalarial therapy in geographical locations where both species
are endemic. Further studies optimizing the selectivity and in vivo efficacy of HDAC inhibitors in Plasmodium
spp. and defining drug interaction with common antimalarial compounds are warranted to investigate the role
of HDAC inhibitors in antimalarial therapy.
Malaria is a major public health issue in more than 100
countries with 40% of the world’s population at risk of acquir-
ing the disease (21). Early diagnosis, followed by prompt and
effective treatment, remains a cornerstone of malaria control
programs (47). However, the effectiveness of this strategy is
compromised by the emergence and spread of drug-resistant
malaria. Most antimalarial drug research has focused on the
treatment of Plasmodium falciparum, the dominant species in
sub-Saharan Africa. However, outside Africa, P. falciparum
and Plasmodium vivax are sympatric, with the latter species
often accounting for half of malaria episodes. In Papua, Indo-
nesia, P. vivax has become highly resistant to chloroquine and
sulfadoxine-pyrimethamine (36, 41), with evidence now emerg-
ing of declining chloroquine efficacy throughout most areas
where vivax malaria is endemic (11). Reports from the island
of New Guinea, where chloroquine resistance is highly preva-
lent, have demonstrated an association between vivax malaria
and severe disease and death (5, 17, 35, 45). In this and other
regions where drug resistance has emerged, new treatment
strategies that focus on different plasmodial targets are ur-
gently needed for both P. falciparum and P. vivax.
In eukaryotes, histone deacetylase (HDAC) and histone
acetyltransferase (HAT) enzymes control the acetylation of
both histones and nonhistone proteins and are thus important
for a variety of vital cellular functions, such as transcription,
DNA replication and repair, cell signaling, as well as cell cycle
regulation and differentiation (49, 50). HDACs have been rec-
ognized as therapeutic targets in cancer cells for over a decade,
with one hydroxamate-based HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA) (Vorinostat), approved for the treat-
ment of persistent or refractory T-cell lymphoma (18). More
recently, HDACs have been identified as important regulators
of transcription in P. falciparum (7, 14, 16, 22). HDAC inhib-
itors have been shown to have activity against apicomplexan
parasites, raising their potential as a new class of antimalarial
compounds (3, 23, 33).
The principal aims of this study were to investigate the ex
vivo susceptibility profiles of antimalarial HDAC inhibitors
against multidrug-resistant clinical isolates of P. falciparum and
P. vivax in Papua, Indonesia, and to examine the stage-specific
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actions of these compounds. The three HDAC inhibitors com-
pared in this study were the clinically approved antitumor
compound SAHA, which has in vitro 50% inhibitory concen-
trations (IC50s) against P. falciparum laboratory lines of 100
to 300 nM (12), and two other structurally related hydroxam-
ate-based compounds with greater in vitro activity against lab-
oratory lines (2-ASA-9 with an IC50 of 15 to 39 nM and
2-ASA-14 with an IC50 of 13 to 33 nM [2-ASA-9 and 2-ASA-14
are 2-aminosuberic acid-based HDAC inhibitors]; Fig. 1).
These compounds contain a hydroxamic acid zinc binding
group and are currently the most promising class of HDAC
inhibitors under investigation for use against malaria.
MATERIALS AND METHODS
Compounds. The synthesis, purification, and characterization of 2-amino-
suberic acid-based HDAC inhibitors (2-ASA-9 and 2-ASA-14; Fig. 1) have been
previously described (24). Suberoylanilide hydroxamic acid (SAHA) was pur-
chased from Sigma. All compounds were prepared as 10 mM stock solutions in
dimethyl sulfoxide (DMSO). Drug plates were then predosed by diluting the
compounds in 50% ethanol followed by lyophilization and storage at 4°C.
Field location and sample collection. Between April and September 2008,
Plasmodium isolates were collected from patients attending malaria clinics in
Timika, Papua province, Indonesia, a region where multidrug-resistant strains of
both P. vivax and P. falciparum are endemic (25, 36, 38). Patients with symptom-
atic malaria presenting to an outpatient facility were recruited into the study if
they presented with single-species infections of either P. falciparum or P. vivax.
Parasite counts were determined on Giemsa-stained thick films as the number of
parasites per 200 white blood cells (WBC), and peripheral parasitemia was
calculated assuming a white cell count of 7,300 l1. Only isolates with a para-
sitemia of between 2,000 l1 and 80,000 l1 were selected for ex vivo analysis.
Since previous studies have highlighted a major difference in the stage-specific
activities of chloroquine and amodiaquine, isolates of P. vivax were processed
only if the majority of asexual forms were at the ring stage (38). Patients treated
with antimalarial drugs in the month prior to sampling were excluded from the
study. Venous blood (5 ml) was collected by venipuncture, and after removal of
host white blood cells using CF 11 cellulose (37), packed infected red blood cells
(IRBC) were used for the ex vivo drug susceptibility assay.
Ex vivo drug susceptibility assay. Drug susceptibility of P. vivax and P. falcip-
arum isolates was measured using a protocol modified from the WHO microtest
as described previously (38, 39). Two hundred microliters of a 2% hematocrit
blood medium mixture (BMM), consisting of RPMI 1640 medium plus 10%
AB human serum (P. falciparum) or McCoy’s 5A medium plus 20% AB
human serum (P. vivax) was added to each well of predosed drug plates con-
taining 11 serial concentrations (2-fold dilutions) of the following antimalarial
drugs (maximum concentration shown in parentheses): chloroquine (2,992 nM),
amodiaquine (80 nM), piperaquine (769 nM), mefloquine (338 nM), and arte-
sunate (25 nM) and the three HDAC inhibitors SAHA (2,000 nM), 2-ASA-9
(1,000 nM), and 2-ASA-14 (1,000 nM). A candle jar was used to mature the
parasites at 37.5°C for 24 to 56 h. Incubation was stopped when 40% of
ring-stage parasites had reached the mature schizont stage in the drug-free
control.
Thick blood films made from each well were stained with 5% Giemsa solution
for 30 min and examined microscopically. Differential counts of 200 asexual
parasites in both the preincubation and test slides were classified into ring stage,
mature trophozoites, and schizonts. To ensure optimal maturity, ease of parasite
identification, and reduction of parasite classification error between microsco-
pists, only schizonts with at least five well-defined chromatin dots were classified
as schizonts at harvest. Free merozoites and gametocytes were not included in
the count.
The number of schizonts per 200 asexual-stage parasites was determined for
each drug concentration and normalized to that of the control well. The dose-
response data were analyzed using nonlinear regression analysis (WinNonLin
4.1; Pharsight Corporation), and the IC50s were derived using an inhibitory
sigmoid Emax model. IC50 ex vivo data were used only from predicted curves
where the maximum effect attributable to the drug (Emax) and the basal effect,
corresponding to the response when the dose of the drug is zero (E0) were within
15% of 100 or 0, respectively.
Data analysis. Data analysis was performed using STATA (version 10.1; Stata
Corp., College Station, TX) and GraphPad Prism (version 5) software. The
Mann-Whitney U test, Wilcoxon signed-rank test, and Spearman rank correla-
tion were used for nonparametric comparisons and correlations. In order to
examine the robustness of our observations, we used restricted and stratified
analysis to control for three major confounding factors: (i) the percentage of ring
stages at the start of the assay, (ii) the duration of the assay, and (iii) the initial
parasitemia. Robust regression analysis was performed on log-transformed data.
Ethical approval. Ethical approval for this study was obtained from the ethics
committees of the National Institute of Health Research and Development,
Ministry of Health, Indonesia, and the Menzies School of Health Research,
Casuarina, Darwin, Australia.
RESULTS
Between April and September 2008, ex vivo susceptibility of
the HDAC inhibitors SAHA, 2-ASA-9, and 2-ASA-14 was
tested in clinical isolates from 49 patients presenting with sin-
gle-species infections of either P. vivax (n  25) or P. falcipa-
rum (n  24). Susceptibility profiles on the same isolates were
also tested against chloroquine, amodiaquine, piperaquine,
mefloquine, and artesunate. Adequate growth for harvest (i.e.,
maturation from the ring or trophozoite stage to 40% at the
schizont stage) was successfully achieved in 83% (20/24) of P.
falciparum isolates and 80% (20/25) of P. vivax isolates. Base-
line characteristics of the isolates processed are presented in
Table 1, and the geometric mean IC50s for the two species, in
comparison with published IC50s for laboratory lines, are
shown in Table 2 and Fig. 2. A difference in drug susceptibility
in the two species was observed for amodiaquine, which
showed a higher median IC50 (9.1 versus 5.0 nM) for P. vivax
(P  0.005), and SAHA, which had a higher median IC50 for
P. falciparum (301 versus 170 nM; P  0.001).
Stage-specific antimalarial activity. To investigate the stage-
specific drug susceptibility, isolates with greater than 90% rings
were set up in culture in the presence of drug directly and
again after ex vivo growth to 90% trophozoites in the absence
FIG. 1. Chemical structures of suberoylanilide hydroxamic acid (SAHA) (WR308364) and 2-aminosuberic acid-based HDAC inhibitors,
2-ASA-9 and 2-ASA-14.
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of drug. For P. falciparum, isolates added to the assay at the
trophozoite stage had significantly higher median IC50s for
SAHA (520 nM versus 329 nM) and 2-ASA-14 (467 nM versus
238 nM) than the same isolates exposed to drug at the ring
stage (P  0.036 and P  0.028, respectively; Table 3). The
derived IC50s were also significantly higher for chloroquine,
amodiaquine, piperaquine, and mefloquine, but not for arte-
sunate. For P. vivax, a stage-specific difference in drug re-
sponse was observed only for chloroquine (median IC50 of 841
nM versus 53 nM; P  0.008), and a less-significant difference
was observed for amodiaquine (median IC50 of 21.2 nM versus
10.1 nM; P  0.036; Table 3).
Correlation in antimalarial susceptibility. The drug re-
sponses to the different HDAC inhibitors were positively cor-
related in both P. falciparum and P. vivax isolates (Spearman
rank correlation coefficients [rs] of 0.515 to 0.818; Table 4). In
P. falciparum isolates, inhibition by mefloquine (IC50) corre-
lated positively with SAHA (rs 0.635 and P 0.004), but not
2-ASA-9 or 2-ASA-14. Conversely, in P. vivax, 2-ASA-9 and
2-ASA-14 (IC50), but not SAHA, positively correlated with
mefloquine (rs  0.527 and P  0.030 and rs  0.610 and P 
0.007, respectively). In addition, P. vivax susceptibility to
2-ASA-14 was positively correlated with chloroquine (rs 
0.490 and P  0.028).
DISCUSSION
Inhibitors of histone deacetylase (HDAC) enzymes repre-
sent a promising new class of antimalarial compounds (3).
Suberoylanilide hydroxamic acid (SAHA) (Vorinostat) was li-
censed for use in humans for the treatment of advanced cuta-
neous lymphoma in 2006, and knowledge about the safety and
pharmacokinetics of HDAC inhibitors is accruing (6, 44). In
vitro drug susceptibility testing has demonstrated that several
hydroxamate-based HDAC inhibitors are potent inhibitors
(IC50s in low nanomolar concentrations) of laboratory strains
of P. falciparum and, importantly, display promising selectivity
for malaria parasites versus mammalian cell lines (100 fold),
depending on the inhibitor and cell lines used (2, 12).
TABLE 1. Baseline characteristics of isolates for which ex vivo
assay was accomplished
Baseline characteristic
Value for species:
P. falciparum P. vivax
Total no. of isolates
reaching harvest
20 20
Median (range) delay from
venipuncture to start of
culture (h)
2.4 (1.6–4.9) 2.5 (1.6–3.7)
Median (range) duration of
assay (h)
46 (41–50) 48 (43–53)
Geometric mean (95% CI)a
parasitemia (no. of
asexual parasites/l)
22,622 (11,900–43,001) 11,675 (7,527–18,110)
Median initial % (range) of
parasites at ring stage
100b 94 (54–100)
Mean (95% CI) schizont
count at harvest
46 (39–52) 40 (35–44)
a 95% CI, 95% confidence interval.
b No range given (all values were 100%).
TABLE 2. Overall ex vivo drug susceptibility for each drug according to the species tested
Antimalarial
Mean IC50 (nM)
for P. falciparum
lab linesa
P. falciparum P. vivax
CQs CQr n (%)b Median IC50 (nM) (range) n (%) Median IC50 (nM) (range)
Chloroquine 12 240 20 (100) 30.2 (6.4–97.1) 20 (100) 40.4 (8.8–81.4)
Amodiaquine 2 8 20 (100) 5.0 (1.0–28.6) 19 (95) 9.1 (2.8–16.0)
Piperaquine 3 11 20 (100) 10.8 (4.4–46.9) 20 (100) 13.2 (3.4–38.4)
Mefloquine 11 8 19 (95) 6.3 (1.7–21.3) 18 (90) 7.7 (1.5–23.2)
Artesunate 2 1 20 (100) 0.92 (0.31–4.1) 20 (100) 0.74 (0.09–1.42)
SAHA 247 161 19 (95) 301 (120–484) 20 (100) 170 (67–281)
2-ASA-9 15 39 15 (75)c 533 (199–964) 19 (95) 503 (203–766)
2-ASA-14 13 33 18 (90)d 266 (87–704) 20 (100) 278 (121–781)
a Mean IC50s (in vitro growth quantified by 3H	hypoxanthine incorporation) as previously published for chloroquine (8, 9), amodiaquine (1, 19), piperaquine (1, 30),
mefloquine (1, 10), artesunate (1, 10) (the chloroquine-sensitive and -resistant lines were 3D7 and K1, respectively), SAHA (12), 2-ASA-9 (2), and 2-ASA-14 (2) (the
chloroquine-sensitive and -resistant laboratory lines, respectively, were D6 and W2 for SAHA and 3D7 and Dd2 for 2-ASA-9 and 2-ASA-14). CQs, chloroquine-
sensitive laboratory strain; CQr, chloroquine-resistant laboratory strain.
b n, total number of assays with acceptable IC50; %, total number of assays with acceptable IC50/number of assays with adequate growth harvested.
c No IC50 estimates of 2-ASA-9 for four P. falciparum isolates and one P. vivax isolate (MIC  1,000 nM).
d No IC50 estimate of 2-ASA-14 for one P. falciparum isolate (MIC  1,000 nM).
FIG. 2. Ex vivo sensitivity (IC50) of clinical field isolates of P. fal-
ciparum (closed circles) and P. vivax (open circles) from Papua, Indo-
nesia, to SAHA, 2-ASA-9, and 2-ASA-14. Each symbol represents the
IC50 for one patient. Each horizontal bar represents the median IC50
for the group of patients.
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In the present study, we compared the ex vivo activities of
three hydroxamate-based HDAC inhibitors against multidrug-
resistant clinical isolates of P. falciparum and P. vivax. This is
the first report of antimalarial activity of this class of com-
pounds directly against clinical isolates and against P. vivax
parasites. The derived potencies (IC50) ranged from 87 to 964
nM against P. falciparum and 67 to 766 nM for P. vivax. This
level of drug activity was within the range of well-tolerated
plasma drug concentrations observed in phase 1 clinical drug
trials in oncology patients (26, 27). However, the ex vivo sus-
ceptibility of clinical isolates of P. falciparum to HDAC inhib-
itors was significantly lower than previously reported in cul-
ture-adapted P. falciparum laboratory strains (Table 2).
Although some of this difference may be explained by the level
of multidrug resistance in Papua, Indonesia, the IC50s for chlo-
roquine were not excessive (median of 30 nM) and significantly
lower than that reported for the chloroquine-resistant labora-
tory strain W2 (400 nM; Table 2). An alternative explanation is
the difference in assay methodology. Previous studies em-
ployed proliferation-based growth inhibition assays of culture-
adapted laboratory strains with in vitro growth quantified by
[3H]hypoxanthine incorporation (4), whereas in the present
study, inhibitory effects were determined in isolates fresh from
the patient with quantification of ex vivo schizont maturation
assessed by microscopy (38). This phenomenon (i.e., micro-
scopic assessment of schizont maturation producing higher
IC50s than those derived from radioisotopic incorporation) has
been described previously (46). In addition, even by applying
the same methodology (i.e., [3H]hypoxanthine incorporation)
but using different assay durations, IC50 estimates derived by a
one-cycle assay (42 h) can be 2- to 6-fold higher than the
estimates derived from the standard assay (72 h) (29). In our
study, IC50s in chloroquine-sensitive and -resistant laboratory
strains (K1 and 3D7, respectively) assessed by using the schi-
zont maturation assay were indeed higher (700 to 1,000 nM)
than the reported values derived by the isotopic assay (15 to
300 nM).
Our study also presents data for the first time on the ex vivo
activity of HDAC inhibitors against the second most significant
malaria parasite, P. vivax. On the basis of sequence homology,
three class I/II HDAC homologues have been identified in
P. falciparum—the class I HDAC homologue (P. falciparum
HDAC 1 [PfHDAC1]) and two less-conserved putative HDACs
(PfHDAC2 and PfHDAC3) about which little is known. Ho-
mologues for all three of these genes are present in other
Plasmodium species, including P. vivax. The other HDAC ho-
mologues cannot be ruled out as possible targets of HDAC
inhibitors in P. falciparum, and furthermore, a correlation be-
tween HDAC inhibitors with selective antimalarial action on
parasite HDACs versus mammalian cell HDACs has not yet
been demonstrated. However, recombinant PfHDAC1 has re-
cently been generated, and the activity of this enzyme has been
shown to be inhibited by hydroxamate-based HDAC inhibitors
(32). PfHDAC1 and the P. vivax homologue (PlasmoDB gene
identification [ID] PVX_099700) share 95% sequence iden-
tity at the amino acid level, and preliminary homology model-
ing using the same alignment as for an in silico PfHDAC1
homology model previously generated by us (2) revealed no
TABLE 3. Ex vivo drug susceptibility for paired isolates tested at the ring (90% before culture) and
trophozoite (90% after culture) stage
Antimalarial
P. falciparum assay P. vivax assay
na
Median IC50 (range) (nM) for:
Pb n
Median IC50 (range) (nM) for:
P
Rings Trophozoites Rings Trophozoites
Chloroquine 8 30.2 (14.0–97.1) 63.2 (21.0–673.3) 0.036 9 53.0 (8.8–81.4) 841.4 (133–1930) 0.008
Amodiaquine 8 5.7 (1.0–28.6) 9.6 (4.5–40.5) 0.025 8 10.1 (3.9–15.5) 21.1 (4.0–36.3) 0.036
Piperaquine 8 11.5 (4.4–46.9) 87.6 (30.4–692.7) 0.012 9 15.5 (3.7–34.8) 15.9 (1.32–42.5) 0.515
Mefloquine 6 6.4 (2.7–12.7) 19.9 (6.4–22.5) 0.046 7 9.2 (1.5–23.2) 10.2 (2.3–27.2) 0.612
Artesunate 8 0.88 (0.31–4.11) 1.19 (0.59–4.18) 0.400 8 0.75 (0.09–1.03) 0.39 (0.2–1.09) 0.484
SAHA 8 329 (232–482) 520 (346–1016) 0.036 9 159 (67–223) 147 (40–229) 0.767
2-ASA-9 4 492 (463–533) 519 (362–988) 1.000 9 545 (203–710) 438 (149–2491) 0.767
2-ASA-14 6 238 (209–704) 467 (273–1043) 0.028 9 327 (121–502) 214 (145–588) 0.110
a n is the number of paired isolates.
b The P values compare the median IC50 values for rings and trophozoites by the Wilcoxon rank sum test. The statistically significant values are shown in boldface
type.
TABLE 4. Correlation coefficients (rs) for ex vivo antimalarial
susceptibilities in P. falciparum and P. vivax
Antimalarial
combination
All P. falciparum isolates All P. vivax isolates
Correlationa Pb dfc Correlation P df
SAHA-chloroquine 0.367 0.123 18 0.012 0.960 19
SAHA-amodiaquine 0.167 0.495 18 0.363 0.127 18
SAHA-piperaquine 0.158 0.519 18 0.239 0.310 19
SAHA-mefloquine 0.635 0.004 18 0.191 0.448 17
SAHA-artesunate 0.156 0.523 18 0.300 0.212 18
SAHA–2-ASA-9 0.818 <0.001 14 0.519 0.023 18
SAHA–2-ASA-14 0.515 0.029 17 0.523 0.018 18
2-ASA-9–chloroquine 0.418 0.121 14 0.307 0.201 18
2-ASA-9–amodiaquine 0.104 0.713 14 0.401 0.099 19
2-ASA-9–piperaquine 0.282 0.308 14 0.209 0.391 18
2-ASA-9–mefloquine 0.450 0.092 14 0.527 0.030 16
2-ASA-9–artesunate 0.057 0.840 14 0.174 0.489 17
2-ASA-9–2-ASA-14 0.662 0.010 13 0.542 0.017 18
2-ASA-14–chloroquine 0.123 0.627 17 0.490 0.028 19
2-ASA-14–amodiaquine 0.108 0.669 17 0.321 0.180 18
2-ASA-14–piperaquine 0.389 0.111 17 0.087 0.715 19
2-ASA-14–mefloquine 0.123 0.627 17 0.610 0.007 17
2-ASA-14–artesunate 0.113 0.657 17 0.233 0.336 18
a Spearman rank correlation coefficients (rs) are shown. The statistically significant
values are shown in boldface type.
b The P values show the significance of the correlation between each pair of
drugs, with those reaching statistical significance shown in boldface type.
c df, degrees of freedom.
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substituted residues near the active site that were different
(D. P. Fairlie and A. J. Lucke, unpublished results). There is
currently no homology model available for the other PfHDACs
due to limited sequence similarity with other eukaryotic
HDAC enzymes.
In view of the confounding effects of stage specificity and
duration of assay for drug susceptibility testing in P. vivax (38,
40), we have adopted more-stringent criteria for our P. vivax
assay. In the present study, only isolates with more than 70% of
the parasites at the ring stage were selected for testing and with
culture maintained for a minimum of 30 h prior to harvest. Our
results for P. vivax isolates tested at both the ring and tropho-
zoite stages confirm the marked stage specificity of action of
chloroquine, with trophozoites being almost completely resis-
tant to the effect of the drug (38, 40). In contrast, the stage-
specific action in P. falciparum was modest, with IC50s less than
2-fold higher for trophozoite stages compared to ring stages.
The results with HDAC inhibitors are consistent with a previ-
ous study in which the effect of continual exposure of P. fal-
ciparum line Dd2 to 2-ASA-9 and 2-ASA-14 was examined at
the ring stage (18 h after invasion), trophozoite stage (26 h
after invasion), and schizont stage (38 h after invasion). Mi-
croscopic examination showed that all stages were inhibited,
with very small numbers of invasive merozoites being released
from schizonts (2).
The ex vivo activity between the HDAC inhibitors was
strongly correlated (rs  0.515 to 0.818; Table 4). Whereas the
drug susceptibility of SAHA was correlated with mefloquine in
P. falciparum (rs  0.635), this did not reach statistical signif-
icance in P. vivax. Conversely, the activities of 2-ASA-9 and
2-ASA-14 were highly correlated with mefloquine in P. vivax,
but not in P. falciparum. The statistical significance of our
observations may simply reflect the small sample size of the
study and intrinsic variance of our assay. Alternatively, ex vivo
drug efficacy may not be determined solely by structural dif-
ferences in the HDAC inhibitors and their plasmodial targets.
While cross-susceptibility between HDAC inhibitors and chlo-
roquine or mefloquine has not been observed in sensitive and
resistant laboratory strains (2, 12), the differences in correla-
tion profiles for P. falciparum and P. vivax may indicate differ-
ent susceptibility profiles in these species. Molecular mecha-
nisms underlying chloroquine resistance are likely to differ
significantly between P. vivax and P. falciparum (31, 43). How-
ever, this is not the case for mefloquine susceptibility, which
has been correlated with increased copy number of the mdr1
gene (P-glycoprotein) in both species (34, 42). There is limited
data on reduced susceptibility to HDAC inhibitors in eukary-
otic cells, but mdr1-mediated tolerance has been reported for
the non-hydroxamate-based compounds apicidin and dep-
sipeptide (FK-228) in several cancer cell lines (28, 48). How-
ever, there is also evidence for mdr1-independent mechanisms
(15), and a more recent study has shown that HDAC inhibitors
were able to promote cell line-specific and reversible induc-
tion of multiple drug transporter genes (20). Antimalarial
resistance is postulated to be a multigenic process (13), and
it is possible that reduced Plasmodium susceptibility to HDAC
inhibitors will occur. However, since HDAC inhibitors have an
effect on multiple vital eukaryotic cell functions (49) and po-
tentially act on both histone and non-histone-related pathways,
it is difficult to predict exactly how Plasmodium will develop
resistance to this drug class.
In our study, hydroxamate-based HDAC inhibitors SAHA,
2-ASA-9, and 2-ASA-14 showed potent ex vivo efficacy against
multidrug-resistant Plasmodium field isolates. Importantly, ex
vivo activity of HDAC inhibitors against P. vivax was compa-
rable to that in P. falciparum, suggesting that HDAC inhibitors
may be promising candidates for antimalarial therapy in geo-
graphical areas where both species are endemic. Elucidation of
the species-specific structure of HDAC analogues in Plasmo-
dium should facilitate molecular design aimed at optimizing
the selectivity and efficacy of HDAC inhibitors. Studies as-
sessing the comparative clinical efficacy in Plasmodium spe-
cies and defining drug interaction with common antimalarial
compounds will reveal further the potential of HDAC in-
hibitors in antimalarial therapy.
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